Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by
inhibiting angiogenesis. In 2018, Lenvatinib was approved for the first-line treatment of …

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related
deaths worldwide, however, current clinical diagnostic and treatment approaches remain …

Amino acids metabolism, especially aspartate metabolism, is often altered in human cancers
including hepatocellular carcinoma (HCC) and this metabolic remodeling is required for …

TUBA1C, a microtubule component, contributes to the development of several cancers. Our
purpose was to study the expression of TUBA1C, its potential prognostic value, and its …

Sorafenib is the first line drug for hepatocellular carcinoma (HCC) therapy. However, HCC
patients usually acquire resistance to sorafenib treatment within 6 months. Recent …

Tubulin alpha 1b (TUBA1B) is an important microtubule isoform that is involved in the
formation of the cytoskeleton. The objective of our study was to explore the potential of …

Some long non-coding RNAs (lncRNAs) have been documented to be involved in cancer
progression and anticancer drug resistance in hepatocellular carcinoma (HCC). Thus …

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death in people, and
a common primary liver cancer. Lacking early diagnosis and a high recurrence rate after …

Pyroptosis is an inflammatory form of programmed cell death that is involved in various
cancers, including hepatocellular carcinoma (HCC). Long non-coding RNAs (lncRNAs) …

Background: Accumulating evidence indicates that type 2 diabetes mellitus (T2DM) is a risk
factor for hepatocellular carcinoma (HCC), and T2DM-associated HCC represents a …